Biotech wins $16.5 million in drug royalties dispute
18-10-2022
Otsuka says Teva’s REXULTI generic infringes patents
24-02-2022
Israel imports patented antivirals for treating COVID-19
24-03-2020
JHVEphoto / Shutterstock.com
The state of Israel has sued Teva Pharmaceuticals for $100 million over alleged unpaid royalties relating to its multiple sclerosis drug, Copaxone.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Teva, Israel, Copaxone, royalties, research, state, big pharma
